Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates

Core Insights - Arcus Biosciences, Inc. reported a quarterly loss of $1.03 per share, which was better than the Zacks Consensus Estimate of a loss of$1.17, representing an earnings surprise of 11.97% [1] - The company generated revenues of $36 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 9.67$31 million in the same quarter last year [2] - Arcus Biosciences shares have declined approximately 31.8% year-to-date, contrasting with the S&P 500's gain of 1.7% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$1.09 on revenues of$37.52 million, while for the current fiscal year, the estimate is -$4.73 on revenues of$111.81 million [7] - The estimate revisions trend for Arcus Biosciences is mixed, leading to a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Arcus Biosciences belongs, is currently ranked in the top 27% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]